This study examines the association between GLP-1 agonist use and BMI among obese adults with T2DM while adjusting for cardiovascular comorbidities and other key patient characteristics, including age, sex, race/ethnicity, and insurance type. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.